Mohammad Saleh, MD
Endocrinology, Diabetes & Metabolism · Dearborn, MINPI 1639195456
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 1,130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations.
Across 1,130 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$3K
- Novo Nordisk$3K
- Amgen$2K
- Corcept Therapeutics$1K
- AstraZeneca$976
- Xeris Pharmaceuticals, Inc.$837
- plus $8K from 54 others
What the payments were for
- Food & beverage$18,693100%
- Education$720%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$125
- ZEPBOUND$125
- Wegovy$117
- TEPEZZA$107
- MINIMED 780G$100
How this compares
$18,765 in reported general payments places this provider in the 85th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 744 | $1,339,128 |
| JardianceEmpagliflozin | 560 | $661,156 |
| MounjaroTirzepatide | 404 | $590,384 |
| TrulicityDulaglutide | 287 | $445,125 |
| JanuviaSitagliptin Phosphate | 250 | $268,259 |
| FarxigaDapagliflozin Propanediol | 181 | $183,347 |
| Tresiba Flextouch U-100Insulin Degludec | 232 | $176,324 |
| Tresiba Flextouch U-200Insulin Degludec | 93 | $163,010 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 58 | $139,477 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 131 | $119,907 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 632 | $112,927 |
| Humalog Kwikpen U-100Insulin Lispro | 263 | $83,934 |
| Novolog FlexpenInsulin Aspart | 275 | $81,479 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 35 | $79,762 |
| TradjentaLinagliptin | 62 | $67,838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $2,608 | $1,383,820805 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $3,074 | $1,051,348739 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $20 | $744,704637 claims |
| MerckJanuvia, Janumet Xr, Janumet | $438 | $329,433316 claims |
| AstraZenecaFarxiga | $976 | $183,347181 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $750 | $51,49244 claims |
| Johnson & JohnsonInvokana | $95 | $39,59829 claims |
| AmgenProlia | $1,893 | $37,00722 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $371 | $14,6831,208 claims |
| AbbVieSynthroid | $170 | $12,263128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Dearborn
- Opada AlzohailiDearborn$33K
- Ali AchiraDearborn$9K
- Sara TothDearborn$8K
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.